Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Federalinoje Gosudarstvennoje Budzhetnoje Uchrezhdenie Nauki Tikookeansky manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This prosecution is being conducted by a lone distinct examiner and is situated within a lone distinct art unit. This suggests a very specific technical focus for the organization's current active patent filings. The organization's focus on Biotechnology & Pharmaceuticals indicates a commitment to scientific research in these fields.
The busiest examiner for this portfolio is BELYAVSKYI, MICHAIL A, who is responsible for 1 busiest examiner pending office action. This accounts for the entirety of the organization's pending office actions. For practitioners, this means that the prosecution outcome is highly dependent on this examiner's review. The presence of a lone distinct examiner and a lone distinct art unit indicates that the organization's current active intellectual property is focused on a specific area, making the successful resolution of this 1 pending office action a key priority for the organization.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELYAVSKYI, MICHAIL A | 1 | 63.9% | +28.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17926318 | DRUG WITH PROLONGED ANALGESIC ACTION | BELYAVSKYI, MICHAIL A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17926318 | DRUG WITH PROLONGED ANALGESIC ACTION | BELYAVSKYI, MICHAIL A | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17926318 | DRUG WITH PROLONGED ANALGESIC ACTION | BELYAVSKYI, MICHAIL A | 1644 | §103§112 | Non-Final OA | — | Pending | Nov 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFederalinoje Gosudarstvennoje Budzhetnoje Uchrezhdenie Nauki Tikookeansky has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michail A Belyavskyi has the most, with 1 of Federalinoje Gosudarstvennoje Budzhetnoje Uchrezhdenie Nauki Tikookeansky's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
